| 2027-06-01in 280 d | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | AAPGAscentage Pharma Group Inc. | Phase 1/2 | Solid Tumors | Recruiting |
| 2027-06-01in 280 d | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | AZNAstraZeneca | Phase 2 | Gastric Cancer | Recruiting |
| 2027-06-01in 280 d | Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants | BMYBristol-Myers Squibb | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-06-01in 280 d | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | EIKNEikon Therapeutics | Phase 1/2 | Solid Tumors | Recruiting |
| 2027-06-01in 280 d | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer | IBRXImmunityBio, Inc. | Phase 1 | Pancreatic Cancer | Not yet recruiting |
| 2027-06-01in 280 d | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | INCYIncyte Corporation | Phase 2 | Graft-Versus-Host Disease | Active, not recruiting |
| 2027-06-01in 280 d | A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany | SNYSanofi | — | Eosinophilic Esophagitis | Recruiting |
| 2027-06-02in 281 d | FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | PFEPfizer | Phase 1 | Atopic Dermatitis | Recruiting |
| 2027-06-02in 281 d | Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | SNYSanofi | Phase 3 | Pruritus | Recruiting |
| 2027-06-03in 282 d | Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM | AZNAstraZeneca | — | ATTR Amyloidosis | Not yet recruiting |
| 2027-06-03in 282 d | A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® | NVONovo Nordisk A/S | — | Hemophilia A | Enrolling by invitation |
| 2027-06-04in 283 d | A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting | PFEPfizer | — | Pneumonia | Recruiting |
| 2027-06-06in 285 d | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Sickle Cell Disease | Active, not recruiting |
| 2027-06-07in 286 d | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | AZNAstraZeneca | Phase 2 | Asthma | Recruiting |
| 2027-06-07in 286 d | Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | SNYSanofi | Phase 3 | Pneumococcal Disease | Recruiting |
| 2027-06-09in 288 d | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Thalassemia | Recruiting |
| 2027-06-11in 290 d | Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | AZNAstraZeneca | Phase 3 | Heart Failure and Impaired Kidney Function | Recruiting |
| 2027-06-11in 290 d | Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis | AZNAstraZeneca | Not applicable | Suspected Asthma | Recruiting |
| 2027-06-14in 293 d | An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant | REGNRegeneron Pharmaceuticals | — | Chronic Kidney Disease | Recruiting |
| 2027-06-15in 294 d | Study of DONQ52 in Active Celiac Disease | 4519.TChugai Pharmaceutical | Phase 2 | Celiac Disease | Recruiting |
| 2027-06-15in 294 d | TROP2 NMR Concordance Study | AZNAstraZeneca | — | Lung Cancer | Not yet recruiting |
| 2027-06-16in 295 d | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | MRNAModernaTX, Inc. | Phase 4 | COVID-19 | Active, not recruiting |
| 2027-06-16in 295 d | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | PFESeagen, a wholly owned subsidiary of Pfizer | Phase 1 | Lung Cancer | Recruiting |
| 2027-06-17in 296 d | A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration | BMYBristol-Myers Squibb | Phase 1 | Alzheimer's Disease | Not yet recruiting |
| 2027-06-18in 297 d | A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma | PFEPfizer | Phase 1 | Asthma | Recruiting |
| 2027-06-18in 297 d | A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | REGNRegeneron Pharmaceuticals | Phase 3 | Monogenic Obesity | Recruiting |
| 2027-06-19in 298 d | Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines | 000100.KSYuhan Corporation | Phase 2 | Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | Recruiting |
| 2027-06-21in 300 d | A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | BMYBristol-Myers Squibb | Phase 1 | Schizophrenia | Recruiting |
| 2027-06-21in 300 d | Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | SNYSanofi | Phase 2 | Asthma | Active, not recruiting |
| 2027-06-22in 301 d | A Study to Learn About mRNA Vaccines Against Influenza in Adults | PFEPfizer | Phase 2 | Healthy Adults | Recruiting |
| 2027-06-23in 302 d | A Study of LAD603 in Adults With Alopecia Areata | ALM.MCAlmirall, S.A. | Phase 2 | Alopecia Areata | Recruiting |
| 2027-06-25in 304 d | Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | AZNAstraZeneca | Phase 3 | Asthma | Active, not recruiting |
| 2027-06-25in 304 d | Study of Patient With Frequent Exacerbations in Moscow | AZNAstraZeneca | — | COPD | Recruiting |
| 2027-06-28in 307 d | A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | BMYBristol-Myers Squibb | Phase 3 | Bipolar Disorder | Recruiting |
| 2027-06-28in 307 d | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis | BMYBristol-Myers Squibb | Phase 1 | Rheumatoid Arthritis | Recruiting |
| 2027-06-28in 307 d | PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis | MMSIMerit Medical Systems, Inc. | — | Chronic Kidney Disease | Recruiting |
| Jun 2027≤ 309 d | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | 000100.KSYuhan Corporation | Phase 1/2 | Solid Tumors | Recruiting |
| 2027-06-30in 309 d | A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration | 4503.TAstellas Pharma Inc | Phase 4 | Age-Related Macular Degeneration | Active, not recruiting |
| Jun 2027≤ 309 d | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | ABBVAbbVie | Phase 2 | Multiple Myeloma | Active, not recruiting |
| Jun 2027≤ 309 d | Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | ABBVAbbVie | Phase 1 | Solid Tumors | Active, not recruiting |
| Jun 2027≤ 309 d | Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease | ABBVAbbVie | Phase 3 | Crohn's Disease | Recruiting |
| Jun 2027≤ 309 d | Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease | ABBVAbbVie | — | Parkinson's Disease | Recruiting |
| Jun 2027≤ 309 d | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | AKBAAkebia Therapeutics | Phase 2 | Focal Segmental Glomerulosclerosis | Recruiting |
| Jun 2027≤ 309 d | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | ALKSAlkermes, Inc. | Phase 3 | Narcolepsy | Recruiting |
| Jun 2027≤ 309 d | Clinical Pre-screening Protocol for Ovarian Cancer | ALLRAllarity Therapeutics | — | Ovarian Cancer | Recruiting |
| 2027-06-30in 309 d | HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB | ALNYAlnylam Pharmaceuticals | Phase 2 | Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | Recruiting |
| Jun 2027≤ 309 d | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | ALXOALX Oncology Inc. | Phase 1 | Lung Cancer | Recruiting |
| 2027-06-30in 309 d | A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | AMGNAmgen | Phase 3 | Secondary Hyperparathyroidism | Recruiting |
| 2027-06-30in 309 d | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | AMGNAmgen | Phase 3 | Lung Cancer | Recruiting |
| Jun 2027≤ 309 d | Integrity Implant System Post Market Clinical Follow-Up Study | ANIKAnika Therapeutics, Inc. | Not applicable | Rotator Cuff Tears of the Shoulder | Recruiting |
| Jun 2027≤ 309 d | Study of APR-1051 in Patients With Advanced Solid Tumors | APREAprea Therapeutics | Phase 1 | Solid Tumors | Recruiting |
| Jun 2027≤ 309 d | Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis | ARCTArcturus Therapeutics, Inc. | Phase 2 | Cystic Fibrosis | Recruiting |
| Jun 2027≤ 309 d | Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease | ARWRArrowhead Pharmaceuticals | Phase 1/2 | Alzheimer's Disease | Recruiting |
| Jun 2027≤ 309 d | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | ASMBAssembly Biosciences | Phase 2 | Chronic Hepatitis D Infection | Not yet recruiting |
| Jun 2027≤ 309 d | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | AVLNAvalyn Pharma Inc. | Phase 2 | Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis | Active, not recruiting |
| 2027-06-30in 309 d | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC | AZNAstraZeneca | Phase 3 | Esophageal Cancer | Active, not recruiting |
| 2027-06-30in 309 d | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | AZNAstraZeneca | Phase 1 | Lung Cancer | Recruiting |
| 2027-06-30in 309 d | Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR) | AZNAstraZeneca | — | Asthma | Recruiting |
| 2027-06-30in 309 d | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | AZNAstraZeneca | Phase 3 | Lung Cancer | Active, not recruiting |
| 2027-06-30in 309 d | Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany | AZNAstraZeneca | — | Heart Failure | Active, not recruiting |
| 2027-06-30in 309 d | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | AZNAstraZeneca | Phase 2 | Colorectal Cancer | Recruiting |
| 2027-06-30in 309 d | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | AZNAstraZeneca | Phase 1/2 | Hepatocellular Carcinoma | Recruiting |
| 2027-06-30in 309 d | An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation | AZNAstraZeneca | — | Endometrial Cancer | Recruiting |
| 2027-06-30in 309 d | Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology | AZNAstraZeneca | — | Ovarian Cancer | Recruiting |
| 2027-06-30in 309 d | The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia | AZNAstraZeneca | — | Hypophosphatasia | Recruiting |
| Jun 2027≤ 309 d | The iLet Experience Study | BBNXBeta Bionics, Inc. | — | Type 1 Diabetes | Recruiting |
| 2027-06-30in 309 d | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | BLTEBelite Bio, Inc | Phase 3 | Geographic Atrophy | Active, not recruiting |
| Jun 2027≤ 309 d | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | BMEABiomea Fusion Inc. | Phase 2 | Type 2 Diabetes | Recruiting |
| Jun 2027≤ 309 d | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors | BNTXBioNTech SE | Phase 1 | Solid Tumors | Active, not recruiting |
| Jun 2027≤ 309 d | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | BNTXBioNTech SE | Phase 2 | Lung Cancer | Active, not recruiting |
| Jun 2027≤ 309 d | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa | BNTXBioNTech SE | Phase 2 | Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection | Recruiting |
| Jun 2027≤ 309 d | TheraSphere With Durvalumab and Tremelimumab for HCC | BSXBoston Scientific Corporation | Phase 2 | Hepatocellular Carcinoma | Active, not recruiting |
| 2027-06-30in 309 d | A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure | BSXBoston Scientific Corporation | Not applicable | Atrial Arrhythmia, Intracardiac Echocardiography | Recruiting |
| 2027-06-30in 309 d | TheraSphere Japan Pre-Market Study | BSXBoston Scientific Corporation | Not applicable | Liver Neoplasms | Recruiting |
| Jun 2027≤ 309 d | Investigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses. | CLColgate Palmolive | Phase 4 | Gingival Inflammation | Not yet recruiting |
| Jun 2027≤ 309 d | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | CRSPCRISPR Therapeutics AG | Phase 1 | Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia | Recruiting |
| Jun 2027≤ 309 d | Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD | CRVSCorvus Pharmaceuticals, Inc. | Phase 2 | Atopic Dermatitis | Recruiting |
| Jun 2027≤ 309 d | An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 | DNLIDenali Therapeutics Inc. | Phase 2/3 | Mucopolysaccharidosis II | Enrolling by invitation |
| Jun 2027≤ 309 d | 4D-710 in Adult Patients With Cystic Fibrosis | FDMT4D Molecular Therapeutics | Phase 2 | Cystic Fibrosis Lung | Recruiting |
| Jun 2027≤ 309 d | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | FDMT4D Molecular Therapeutics | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | Active, not recruiting |
| Jun 2027≤ 309 d | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | GENBGenerate Biomedicines | Phase 1 | Urothelial Carcinoma | Recruiting |
| Jun 2027≤ 309 d | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | GILDGilead Sciences | Phase 3 | Breast Cancer | Recruiting |
| Jun 2027≤ 309 d | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | HUMAHumacyte, Inc. | Phase 3 | Chronic Kidney Disease | Active, not recruiting |
| 2027-06-30in 309 d | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | IMNNImunon | Phase 1/2 | Ovarian Cancer | Recruiting |
| 2027-06-30in 309 d | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | INDPIndaptus Therapeutics, Inc | Phase 1/2 | Solid Tumors | Active, not recruiting |
| Jun 2027≤ 309 d | A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure | INKTMiNK Therapeutics | Phase 2 | Pneumonia | Recruiting |
| Jun 2027≤ 309 d | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Familial Chylomicronemia Syndrome | Active, not recruiting |
| Jun 2027≤ 309 d | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | IPH.PAInnate Pharma | Phase 2 | Lung Cancer | Recruiting |
| Jun 2027≤ 309 d | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | IRONDisc Medicine, Inc | Phase 1 | Sickle Cell Disease | Recruiting |
| Jun 2027≤ 309 d | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | KPTIKaryopharm Therapeutics Inc | Phase 2 | Myelofibrosis | Recruiting |
| Jun 2027≤ 309 d | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | KYMRKymera Therapeutics, Inc. | Phase 2 | Atopic Dermatitis | Active, not recruiting |
| Jun 2027≤ 309 d | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | LBRXLB Pharmaceuticals Inc. | Phase 3 | Schizophrenia | Recruiting |
| Jun 2027≤ 309 d | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | LLYEli Lilly and Company | Phase 1 | Bladder Cancer | Recruiting |
| Jun 2027≤ 309 d | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | LLYEli Lilly and Company | Phase 2 | Ulcerative Colitis | Recruiting |
| Jun 2027≤ 309 d | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease | LLYEli Lilly and Company | Phase 2 | Crohn's Disease | Recruiting |
| Jun 2027≤ 309 d | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | LLYEli Lilly and Company | Phase 2 | Alopecia Areata | Recruiting |
| Jun 2027≤ 309 d | A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes | LLYEli Lilly and Company | Phase 1 | Obesity | Not yet recruiting |
| Jun 2027≤ 309 d | A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter | LMATLeMaitre Vascular | Not applicable | Arterial Thromboembolism | Recruiting |
| Jun 2027≤ 309 d | A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters | LMATLeMaitre Vascular | Not applicable | Thrombus, Embolus, Occlusion; Vessel | Recruiting |
| 2027-06-30in 309 d | An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | LUNGPulmonx Corporation | Not applicable | COPD | Recruiting |
| Jun 2027≤ 309 d | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | MANEVeradermics, Inc. | Phase 3 | Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss | Active, not recruiting |
| Jun 2027≤ 309 d | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | MGTXMeiraGTx, LLC | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | Active, not recruiting |
| 2027-06-30in 309 d | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | MIRMMirum Pharmaceuticals, Inc. | Phase 3 | Chronic Hepatitis D Infection | Recruiting |
| Jun 2027≤ 309 d | Study to Assess the Safety and Effectiveness of NMRA-335140-501 | NMRANeumora Therapeutics, Inc. | Phase 3 | Major Depressive Disorder | Active, not recruiting |
| Jun 2027≤ 309 d | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | ORICORIC Pharmaceuticals | Phase 1 | Prostate Cancer | Recruiting |
| Jun 2027≤ 309 d | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | ORKAOruka Therapeutics, Inc. | Phase 2 | Psoriasis | Active, not recruiting |
| Jun 2027≤ 309 d | Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes | PODDInsulet Corporation | — | Type 1 Diabetes | Recruiting |
| Jun 2027≤ 309 d | Post Market Clinical Follow up of ResMed Mask Systems | RMDResMed | Not applicable | Obstructive Sleep Apnea | Recruiting |
| Jun 2027≤ 309 d | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | RNXTRenovoRx | Phase 3 | Locally Advanced Pancreatic Cancer | Recruiting |
| Jun 2027≤ 309 d | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | RVMDRevolution Medicines, Inc. | Phase 1/2 | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC | Recruiting |
| Jun 2027≤ 309 d | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | RXRXRecursion Pharmaceuticals Inc. | Phase 1/2 | Familial Adenomatous Polyposis | Recruiting |
| Jun 2027≤ 309 d | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | SLDBSolid Biosciences Inc. | Phase 1 | Catecholaminergic Polymorphic Ventricular Tachycardia | Recruiting |
| Jun 2027≤ 309 d | An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | SPRYARS Pharmaceuticals, Inc. | Phase 2 | Urticaria Chronic | Recruiting |
| Jun 2027≤ 309 d | Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | SVRASavara Inc. | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | Recruiting |
| Jun 2027≤ 309 d | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | SYRESpyre Therapeutics, Inc. | Phase 2 | Ulcerative Colitis | Recruiting |
| Jun 2027≤ 309 d | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | TNGXTango Therapeutics, Inc. | Phase 1/2 | Pancreatic Cancer | Recruiting |
| Jun 2027≤ 309 d | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | VRCAVerrica Pharmaceuticals Inc. | Phase 3 | Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts | Recruiting |
| 2027-06-30in 309 d | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Type 1 Diabetes | Recruiting |
| Jun 2027≤ 309 d | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | VSTMVerastem, Inc. | Phase 2 | Pancreatic Cancer | Recruiting |
| Jun 2027≤ 309 d | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer | VSTMVerastem, Inc. | Phase 2 | Lung Cancer | Recruiting |
| Jun 2027≤ 309 d | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | VSTMVerastem, Inc. | Phase 2 | Colorectal Cancer | Recruiting |
